Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:36:09.295Z.
Calculation as of: 2026-10-06T13:36:09.295Z.
Quote observation: 2026-10-06T13:34:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47fe9b5a4b5325aa2b63eefeab4e4f99d65252ab4bc117be38c834a5b01498bd
PE RATIO
N/A
Market Cap
$115.44M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.02M
PE Ratio
N/A
TTM Avg
17.69
3Y Avg
17.69
5Y Avg
17.69
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $114.35M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.44M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $112.02M | N/A | 17.69 | 17.69 | 17.69 |
| Genelux Corporation (GNLX)vs › | $117.48M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $117.87M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.75M | N/A | 3.95 | 3.95 | 3.95 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.42M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $110.06M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.88
Forward EPS (Est.)
$-1.33
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
